Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin America Product Supply Expected During the Fourth Quarter of 2022 and the First Half of 2023 Rehovot, Israel, and Hoboken, NJ, July 6, 2022 — Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty […]
Rehovot, Israel, and Hoboken, NJ, June 15, 2022 — Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today the promotions of Shavit Beladev to Vice President responsible for the Company’s Plasma Operations, and Boris Gorelik to Vice President of Business Development and Strategic Programs, both […]
Rehovot, Israel, June 1, 2022 – Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will host a virtual analysts and investors meeting on Tuesday, June 7, 2022, at 12:00 PM Eastern Time to review its growth catalysts. To register for the meeting […]
REHOVOT, Israel – May 17, 2022 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy […]
First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year. Kamada Reiterates Fiscal Year 2022 Revenue Guidance of $125 – $135 Million, Representing a 20% to 30% Increase over 2021 and EBITDA Margins Anticipated Between 12%-15%, More Than 2.5X over 2021 EBITDA. Revenues and Profitability Margins of Recently Acquired Portfolio of Four FDA-Approved […]
Rehovot, Israel, May 11, 2022 — Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2022, prior to the open of the U.S. financial markets on Tuesday, May 17, 2022. Kamada management […]
Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million, Representing a 20% to 30% Increase over 2021; 2022 EBITDA Margins Anticipated Between 12%-15%, Representing More Than 2.5X over 2021 EBITDA. Integration of […]
REHOVOT, Israel – March 15, 2022 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from Amir London, Chief Executive Officer. March 15th, 2022 Dear Shareholders, Colleagues and Business Partners: The recently completed 2021 year was a transformational period […]
New Executives to Strengthen the Company’s U.S. Commercial Operations, Focused on Recently Acquired Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Products, and Planned Opening of New Plasma Collection Centers REHOVOT, Israel – March 14, 2022 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced the […]
Rehovot, Israel, March 2, 2022 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of the U.S. financial markets on Tuesday, March 15, 2022. Kamada management will host an investment community […]